Percutaneous biventricular cardiac assist device in cardiogenic shock and refractory cardiac arrest.

after myocardial infarction. N Engl J Med 2002;347:969–974. 9. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DP, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted S, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo , Diaz R, White HD, Ruda M, Geraldes M, Lawrence J, Harrington R, Wallentin L. Apixaban with antiplatelet therapy therapy after acute coronary syndrome. N Engl J Med 2011;365:699–708. 10. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt D, Bode C, Burton P, Cohen M, Goto S, Fox KAA, Murphy S, Plotnikov AN, Schneider D, Sun X, Verheugt FWA, Gibson CM. Rivaroxaban in patients with a recent coronary syndrome. N Engl J Med 2012;366:9–19. 11. Oldgren J, Wallentin L, Alexander JH, James S, Jönelid B, Steg PG, Sundström J. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 2013;34:1670–1680. 12. Granger GB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn G, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopes-Sendon J, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981–992. 13. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Werner H, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz CD, Fox KAA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–891.